Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver.
暂无分享,去创建一个
Geoffrey Kemball-Cook | Jenny McIntosh | Yunyu Spence | Amit C Nathwani | J. Gray | A. Davidoff | S. Waddington | E. Tuddenham | A. Nathwani | K. Mertens | Koen Mertens | C. Ng | Andrew M Davidoff | Junfang Zhou | G. Kemball-Cook | John T Gray | Catherine Y C Ng | Simon N Waddington | Edward G D Tuddenham | Mariette Boon-Spijker | Junfang Zhou | Yunyu Spence | M. Boon‐Spijker | J. McIntosh | C. Ng | Mariëtte Boon‐Spijker
[1] Brian Seed,et al. Codon usage limitation in the expression of HIV-1 envelope glycoprotein , 1996, Current Biology.
[2] J. Rasko,et al. 1002. Immune Responses to AAV and to Factor IX in a Phase I Study of AAV-Mediated, Liver-Directed Gene Transfer for Hemophilia B , 2004 .
[3] J. Gray,et al. Purification of recombinant adeno-associated virus type 8 vectors by ion exchange chromatography generates clinical grade vector stock. , 2004, Journal of virological methods.
[4] Lili Wang,et al. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[5] Theresa A. Storm,et al. Unrestricted Hepatocyte Transduction with Adeno-Associated Virus Serotype 8 Vectors in Mice , 2005, Journal of Virology.
[6] M. Kay,et al. Inclusion of the hepatic locus control region, an intron, and untranslated region increases and stabilizes hepatic factor IX gene expression in vivo but not in vitro. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.
[7] S. Amadori,et al. Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. , 2004, Blood.
[8] M. Brittan,et al. Permanent phenotypic correction of hemophilia B in immunocompetent mice by prenatal gene therapy. , 2004, Blood.
[9] M. Weitzman,et al. Recruitment of wild-type and recombinant adeno-associated virus into adenovirus replication centers , 1996, Journal of virology.
[10] M. Zoppè,et al. A factor IX-deficient mouse model for hemophilia B gene therapy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[11] D. Russell,et al. DNA-damaging agents greatly increase the transduction of nondividing cells by adeno-associated virus vectors , 1994, Journal of virology.
[12] M. Kay,et al. A Limited Number of Transducible Hepatocytes Restricts a Wide-Range Linear Vector Dose Response in Recombinant Adeno-Associated Virus-Mediated Liver Transduction , 2002, Journal of Virology.
[13] Jody A. Vandergriff,et al. Efficient gene transfer into human cord blood CD34+ cells and the CD34+CD38− subset using highly purified recombinant adeno-associated viral vector preparations that are free of helper virus and wild-type AAV , 2000, Gene Therapy.
[14] R. Samulski,et al. Rescue of adeno-associated virus from recombinant plasmids: Gene correction within the terminal repeats of AAV , 1983, Cell.
[15] E. Freese,et al. Prospects of gene therapy. , 1972, Science.
[16] Theresa A. Storm,et al. Extrachromosomal Recombinant Adeno-Associated Virus Vector Genomes Are Primarily Responsible for Stable Liver Transduction In Vivo , 2001, Journal of Virology.
[17] A. Davidoff,et al. Prospects for gene therapy of haemophilia , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.
[18] A. Davidoff,et al. Sex significantly influences transduction of murine liver by recombinant adeno-associated viral vectors through an androgen-dependent pathway. , 2003, Blood.
[19] A. Nienhuis,et al. Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA. , 2001, Blood.
[20] R. Morgan,et al. The rhesus macaque as an animal model for hemophilia B gene therapy. , 1999, Blood.
[21] O. Christophe,et al. Functional mapping of anti-factor IX inhibitors developed in patients with severe hemophilia B. , 2001, Blood.
[22] R. Kotin,et al. Virus-Mediated Transduction of Murine Retina with Adeno-Associated Virus: Effects of Viral Capsid and Genome Size , 2002, Journal of Virology.
[23] R. Samulski,et al. Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo , 2003, Gene Therapy.
[24] Linda Yang,et al. Cloning and Characterization of Adeno-Associated Virus Type 5 , 1999, Journal of Virology.
[25] E. Tuddenham,et al. Epidemiology of coagulation disorders. , 1992, Bailliere's clinical haematology.
[26] C. Slaughter,et al. Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques. , 2002, Blood.
[27] C. Lewis,et al. Mutation rates in humans. I. Overall and sex-specific rates obtained from a population study of hemophilia B. , 1999, American journal of human genetics.
[28] Arun Srivastava,et al. Adeno-Associated Virus Type 2-Mediated Gene Transfer: Role of Epidermal Growth Factor Receptor Protein Tyrosine Kinase in Transgene Expression , 1998, Journal of Virology.
[29] D. Russell,et al. Design and Packaging of Adeno-Associated Virus Gene Targeting Vectors , 2000, Journal of Virology.
[30] Theresa A. Storm,et al. Rapid Uncoating of Vector Genomes Is the Key toEfficient Liver Transduction with Pseudotyped Adeno-Associated VirusVectors , 2004, Journal of Virology.
[31] R. Samulski,et al. Cross-Packaging of a Single Adeno-Associated Virus (AAV) Type 2 Vector Genome into Multiple AAV Serotypes Enables Transduction with Broad Specificity , 2002, Journal of Virology.
[32] J. Zhang,et al. Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo , 2003, Gene Therapy.
[33] G. Boiteau,et al. J. Virol. Methods , 1996, Journal of Virological Methods.
[34] R. Samulski,et al. Production of High-Titer Recombinant Adeno-Associated Virus Vectors in the Absence of Helper Adenovirus , 1998, Journal of Virology.
[35] M. Weitzman,et al. Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis , 1996, Journal of virology.
[36] P. Lenting,et al. Residues Phe342–Asn346 of Activated Coagulation Factor IX Contribute to the Interaction with Low Density Lipoprotein Receptor-related Protein* , 2003, The Journal of Biological Chemistry.
[37] J. Gray,et al. Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.